U.S. NEUROPATHIC PAIN TREATMENT MARKET ANALYSIS

U.S. Neuropathic Pain Treatment Market, by Drug Type (Pain Relievers (NSAIDS, Opioids (Tramadol, Oxycodone, and Others)), Anti-seizure Medications (Gabapentin, Pregabalin, and Others), Topical Treatments, Antidepressants (Duloxetine, Amitriptyline, Escitalopram, and Others), and Others), by Indication (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Dec 2022
Code : CMI5429
Pages :155
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Increasing product launches or approvals for treating neuropathic pain is expected to boost the market growth over the forecast period. For instance, in August 2020, Averitas Pharma, a specialty pharmaceutical company focusing on non-opioid pain management drugs, and the U.S. subsidiary of Grünenthal, a Germany-based pharmaceutical company, received approval for Qutenza, a capsaicin drug for the treatment of Diabetic Peripheral Neuropathy (DPN) of the feet from the U.S. Food & Drug Administration (U.S. FDA). This cutaneous patch delivers prescription-strength capsaicin directly to the skin.